PeptideDB

WNK-IN-11-d3

CAS No.: 2123483-49-6

WNK-IN-12 is an effective, selective, and orally active WNK1 kinase inhibitor.
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description WNK-IN-12 is an effective, selective, and orally active WNK1 kinase inhibitor.
Synonyms WNK inhibitor-12, WNKIN12, WNK IN 12, WNK inhibitor 12, WNK-IN-12
molecular weight 465.42
Molecular formula C21H18Cl2D3N5OS
CAS 2123483-49-6
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
References 1. Vorontsova I, Donaldson PJ, Kong Z, Wickremesinghe C, Lam L, Lim JC. The modulation of the phosphorylation status of NKCC1 in organ cultured bovine lenses: Implications for the regulation of fiber cell and overall lens volume. Exp Eye Res. 2017 Dec;165:164-174. doi: 10.1016/j.exer.2017.08.009. Epub 2017 Aug 14. PubMed PMID: 28818393. 2. AlAmri MA, Kadri H, Alderwick LJ, Simpkins NS, Mehellou Y. Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal Domains. ChemMedChem. 2017 May 9;12(9):639-645. doi: 10.1002/cmdc.201700077. Epub 2017 Apr 12. PubMed PMID: 28371477. 3. Zhang J, Deng X, Kahle KT. Leveraging unique structural characteristics of WNK kinases to achieve therapeutic inhibition. Sci Signal. 2016 Oct 18;9(450):pe3. Review. PubMed PMID: 27811182. 4. Bhuiyan MIH, Song S, Yuan H, Begum G, Kofler J, Kahle KT, Yang SS, Lin SH, Alper SL, Subramanya AR, Sun D. WNK-Cab39-NKCC1 signaling increases the susceptibility to ischemic brain damage in hypertensive rats. J Cereb Blood Flow Metab. 2017 Aug;37(8):2780-2794. doi: 10.1177/0271678X16675368. Epub 2016 Jan 1. PubMed PMID: 27798271; PubMed Central PMCID: PMC5536788.